[BCR] C.R. Bard, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 223.06 Change: 2.39 (1.08%)
Ext. hours: Change: 0 (0%)

chart BCR

Refresh chart

Strongest Trends Summary For BCR

BCR is in the long-term up 306% in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular products, including percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. The company?s urology products include Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone rem

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS9.97 EPS Growth - 4 Quarters-162.3% EPS Growth - Q/Q-158.05%
EPS Growth - Y/Y-63.37% Sales Growth - 4 Quarters 3.59% Sales Growth - Q/Q4.89% P/E31.56
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA7.06% ROE21.14% ROI9.52%
Current Ratio1.96 Quick Ratio1.61 Long Term Debt/Equity1.08 Debt Ratio0.67
Gross Margin62.29% Operating Margin24.91% Net Profit Margin10.38% Dividend Payout Ratio-19.11%
Dividend Yield
Fundamental Data
Cash From Financing Activities-321.6 M Cash From Investing Activities-26.3 M Cash From Operating Activities507.4 M Gross Profit526.1 M
Net Profit-54.7 M Operating Profit71.1 M Total Assets4.97 B Total Current Assets2.17 B
Total Current Liabilities1.11 B Total Debt1.4 B Total Liabilities3.31 B Total Revenue859.8 M
Technical Data
High 52 week336.55 Low 52 week218.88 Last close331.24 Last change0%
RSI42.7 Average true range1.76 Beta0.51 Volume295.33 K
Simple moving average 20 days-0.42% Simple moving average 50 days-0.32% Simple moving average 200 days6.26%
Performance Data
Performance Week-0.05% Performance Month-1.58% Performance Quart3.43% Performance Half4.95%
Performance Year48.32% Performance Year-to-date47.97% Volatility daily0.35% Volatility weekly0.78%
Volatility monthly1.59% Volatility yearly5.51% Relative Volume251.03% Average Volume588.75 K
New High New Low

News

2018-03-09 11:30:07 | Moody's: Outlook for US medical products and devices industry changed to positive

2018-02-07 16:35:00 | Becton, Dickinson Ready to Sing a New Song

2018-01-05 10:16:19 | KeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance

2018-01-03 16:53:06 | Becton, Dickinson and Company -- Moody's downgrades Becton, Dickinson and Company to speculative grade

2018-01-02 10:28:07 | C.R. Bard, Inc. -- Moody's withdraws C.R. Bard's ratings

2017-12-29 17:10:02 | BD Gets Final Regulatory Approval for Bard Acquisition

2017-12-29 11:33:47 | ETFs with exposure to C.R. Bard, Inc. New Jersey : December 29, 2017

2017-12-29 10:48:00 | BD Completes Bard Acquisition, Creating New Global Health Care Leader

2017-12-29 07:52:12 | Becton, Dickinson BDX, Bard Receive Regulatory Nod in China

2017-12-28 18:40:00 | Huntington Ingalls Industries Set to Join S&P 500; Scientific Games to Join S&P MidCap 400 and Ultra Clean Holdings to Join S&P SmallCap 600

2017-12-28 12:23:07 | Becton, Dickinson and Company -- Moody's downgrades Becton, Dickinson and Company to speculative grade

2017-12-28 09:08:02 | NutriSystem NTRI Adopts Multi-Brand Strategy for 2018

2017-12-28 06:54:00 | BD Statement On MOFCOM Clearance Of Bard Acquisition

2017-12-27 09:06:02 | Becton, Dickinson BDX a Step Closer to Bard Acquisition

2017-12-26 12:43:05 | C.R. Bard, Inc. New Jersey – Value Analysis NYSE:BCR : December 26, 2017

2017-12-22 14:36:00 | BD Statement On FTC Clearance Of Bard Acquisition

2017-12-22 07:35:48 | C.R. Bard, Inc. New Jersey breached its 50 day moving average in a Bearish Manner : BCR-US : December 22, 2017

2017-12-18 14:46:02 | ETFs with exposure to C.R. Bard, Inc. New Jersey : December 18, 2017

2017-12-14 08:11:01 | Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

2017-12-08 11:15:54 | C.R. Bard, Inc. New Jersey : BCR-US: Dividend Analysis : December 08th, 2017 record date : By the numbers : December 8, 2017

2017-12-07 13:01:05 | ETFs with exposure to C.R. Bard, Inc. New Jersey : December 7, 2017

2017-12-03 12:50:08 | How Does C R Bard Inc’s BCR EPS Growth Stack Up Against Industry Performance?

2017-11-30 07:35:13 | What Jabil's new director signals about the company's future

2017-11-29 07:50:00 | Market Trends Toward New Normal in Cloudera, C.R. Bard, Jabil Circuit, Valero Energy, Navient, and Interpace Diagnostics Group — Emerging Consolidated Expectations, Analyst Ratings

2017-11-27 12:15:57 | ETFs with exposure to C.R. Bard, Inc. New Jersey : November 27, 2017

2017-11-27 06:04:00 | 3 Top Diabetes Stocks to Buy Now

2017-11-25 15:32:45 | Paul Tudor Jones: The Global Macro Trader

2017-11-16 06:36:00 | BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines

2017-11-14 08:02:16 | See what the IHS Markit Score report has to say about C R Bard Inc.

2017-11-13 11:50:03 | ETFs with exposure to C.R. Bard, Inc. New Jersey : November 13, 2017

2017-11-13 07:40:00 | Earnings Review and Free Research Report: C.R. Bard’s Revenue Grew 5%; Adjusted EPS Increased 14.3%

2017-11-06 07:10:00 | Corporate News Blog - Medical Technology Company Pulse Biosciences Announces Changes to its Board

2017-11-01 11:53:23 | ETFs with exposure to C.R. Bard, Inc. New Jersey : November 1, 2017

2017-10-30 10:15:23 | C.R. Bard, Inc. New Jersey :BCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017

2017-10-25 17:05:33 | C.R. Bard beats 3Q profit forecasts

2017-10-25 16:15:00 | Bard Announces Third Quarter Results

2017-10-23 11:08:23 | Research Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement

2017-10-23 09:44:01 | EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

2017-10-18 10:17:00 | BD Statement On European Commission Conditional Clearance Of Bard Acquisition

2017-10-17 08:27:12 | Can CR Bard BCR Spring a Surprise This Earnings Season?

2017-10-16 11:06:53 | EU mergers and takeovers Oct 16

2017-10-11 16:15:00 | Bard Declares Quarterly Dividend

2017-09-18 10:35:35 | C.R. Bard, Inc. New Jersey breached its 50 day moving average in a Bearish Manner : BCR-US : September 18, 2017

2017-09-15 12:35:53 | BD Stock Fell 2.7% on September 13: Should Investors Worry?

2017-09-12 09:42:01 | Becton, Dickinson's BCR C.R. Bard Buyout Plans Bode Well

2017-09-05 22:48:34 | C.R. Bard, Inc. New Jersey – Value Analysis NYSE:BCR : September 6, 2017

2017-09-01 10:13:15 | C.R. Bard, Inc. New Jersey breached its 50 day moving average in a Bullish Manner : BCR-US : September 1, 2017

2017-08-29 09:06:01 | C. R. Bard's BCR LUTONIX 035 Gets FDA Pre-Market Approval

2017-08-28 11:36:13 | Becton Dickinson’s Bard Acquisition: On Track, Gaining Momentum

2017-08-28 09:00:00 | C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae